These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2970855)

  • 21. Effects of aqueous extract of Hibiscus sabdariffa on the renin-angiotensin-aldosterone system of Nigerians with mild to moderate essential hypertension: A comparative study with lisinopril.
    Nwachukwu DC; Aneke EI; Obika LF; Nwachukwu NZ
    Indian J Pharmacol; 2015; 47(5):540-5. PubMed ID: 26600645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma renin activity to plasma aldosterone concentration ratio correlates with night-time and pulse pressures in essential hypertensive patients treated with angiotensin-converting enzyme inhibitors/AT1 blockers.
    Spannella F; Giulietti F; Balietti P; Borioni E; Lombardi FE; Ricci M; Cocci G; Landi L; Sarzani R
    J Hypertens; 2017 Nov; 35(11):2315-2322. PubMed ID: 28614094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-exercise reduction in blood pressure in hypertensive subjects: effects of angiotensin converting enzyme inhibition.
    Beaulieu M; Nadeau A; Lacourcière Y; Cléroux J
    Br J Clin Pharmacol; 1993 Oct; 36(4):331-8. PubMed ID: 12959311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of antihypertensive and hormonal effects of captopril and propranolol at rest and during exercise.
    Pickering TG; Case DB; Sullivan PA; Laragh JH
    Am J Cardiol; 1982 Apr; 49(6):1566-8. PubMed ID: 7041599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme.
    MacGregor GA; Markandu ND; Roulston JE; Jones JC
    Br Med J; 1979 Nov; 2(6198):1106-9. PubMed ID: 229941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are angiotensin converting enzyme inhibition and aldosterone antagonism equivalent in hypertensive patients over fifty?
    Plouin PF; Battaglia C; Alhenc-Gélas F; Corvol P
    Am J Hypertens; 1991 Apr; 4(4 Pt 1):356-62. PubMed ID: 2059395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical experience with an oral angiotensin I-converting enzyme inhibitor in hypertensive patients: effects on blood pressure and the renin-aldosterone system by a single dose (author's transl)].
    Mizuno K; Shigetomi S; Haruyama K; Matsui J; Gotho M; Fukuchi S
    Nihon Jinzo Gakkai Shi; 1980 Jan; 22(1):1-11. PubMed ID: 6247526
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of captopril (SQ 14225) on blood pressure, plasma renin activity and angiotensin I converting enzyme activity.
    Larochelle P; Genest J; Kuchel O; Boucher R; Gutkowska Y; McKinstry D
    Can Med Assoc J; 1979 Aug; 121(3):309-16. PubMed ID: 223756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute effects of the new oral angiotensin converting enzyme inhibitor 1-(D-3-acetylthio-2-methylpropanoyl)-L-prolyl-L-phenylalanine (Alacepril) in essential hypertension.
    Mizuno K; Hashimoto S; Kunii N; Tani M; Niimura S; Yabe R; Watari H; Fukuchi S
    Res Commun Chem Pathol Pharmacol; 1985 Aug; 49(2):175-87. PubMed ID: 2997886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immediate and short-term cardiovascular effects of fosinopril, a new angiotensin-converting enzyme inhibitor, in patients with essential hypertension.
    Oren S; Messerli FH; Grossman E; Garavaglia GE; Frohlich ED
    J Am Coll Cardiol; 1991 Apr; 17(5):1183-7. PubMed ID: 1826120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antihypertensive, enzymatic, and hormonal activity of cilazapril, a new angiotensin-converting enzyme inhibitor in patients with mild to moderate essential hypertension.
    Sánchez RA; Traballi CA; Barclay CA; Gilbert HB; Muscará M; Giannone C; Moledo LI
    J Cardiovasc Pharmacol; 1988 Feb; 11(2):230-4. PubMed ID: 2452319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A new principle in long-term treatment of essential hypertension: angiotensin-converting enzyme inhibition (author's transl)].
    Overlack A; Stumpe KO; Heck I; Krück F
    Dtsch Med Wochenschr; 1980 Apr; 105(15):505-9. PubMed ID: 6244920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
    Tiryaki O; Usalan C; Buyukhatipoglu H
    Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haemodynamic and hormonal effects of cilazapril in comparison with propranolol in healthy subjects and in hypertensive patients.
    Kleinbloesem CH; Erb K; Essig J; Breithaupt K; Belz GG
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):309S-315S. PubMed ID: 2527544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potassium as a link between insulin and the renin-angiotensin-aldosterone system.
    Ferrannini E; Galvan AQ; Santoro D; Natali A
    J Hypertens Suppl; 1992 Apr; 10(1):S5-10. PubMed ID: 1619503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency.
    Sica DA; Cutler RE; Parmer RJ; Ford NF
    Clin Pharmacokinet; 1991 May; 20(5):420-7. PubMed ID: 1652404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin converting enzyme inhibitors and moderate hypertension.
    McAreavey D; Robertson JI
    Drugs; 1990 Sep; 40(3):326-45. PubMed ID: 2226219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension.
    Murdoch D; McTavish D
    Drugs; 1992 Jan; 43(1):123-40. PubMed ID: 1372856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparisons of long-term effects between converting enzyme inhibitors and conventional therapy in treating mild to moderate hypertension.
    Lin M; Chiang HT; Chen CY
    Zhonghua Yi Xue Za Zhi (Taipei); 1991 Nov; 48(5):339-50. PubMed ID: 1659934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.
    Biollaz J; Brunner HR; Gavras I; Waeber B; Gavras H
    J Cardiovasc Pharmacol; 1982; 4(6):966-72. PubMed ID: 6185790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.